Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026

Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026

Same author

Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities.

ERJ open research·2026

Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026

Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026

Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025

Search research articles

Related Experiment Video

Updated: May 22, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Advanced pulmonary sarcoidosis.

Florence Jeny¹, Dominique Valeyre², Elyse E Lower³

¹Department of Pulmonology, APHP Avicenne University Hospital, INSERM UMR 1272, University Sorbonne Paris Nord, Bobigny, France.

Journal of Autoimmunity

|March 15, 2025

Summary

This summary is machine-generated.

Advanced pulmonary sarcoidosis can lead to severe outcomes, with pulmonary fibrosis and hypertension being major risks. Current treatments for these advanced lung conditions lack sufficient evidence for clear benefits.

Keywords:

Infliximab Prednisone Pulmonary arterial hypertension Pulmonary fibrosis Pulmonary sarcoidosis

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Related Experiment Videos

Last Updated: May 22, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Area of Science:

Pulmonary Medicine
Rheumatology
Immunology

Background:

Sarcoidosis frequently impacts the lungs, with manifestations varying from asymptomatic cases to fatal outcomes.
Approximately 25% of sarcoidosis patients develop chronic pulmonary disease, posing significant risks.
Advanced pulmonary sarcoidosis is characterized by progressive disease and increased risk of morbidity and mortality.

Purpose of the Study:

To review the key features and diagnostic methods for advanced pulmonary sarcoidosis.
To discuss current therapeutic approaches and the evidence supporting them for chronic pulmonary sarcoidosis.
To highlight the unmet needs in treating pulmonary fibrosis and hypertension in sarcoidosis.

Main Methods:

Review of large retrospective studies and clinical trial data.
Analysis of diagnostic modalities including high-resolution computed tomography (HRCT) and echocardiography.
Assessment of therapeutic strategies targeting chronic inflammation, pulmonary hypertension, and fibrosis.

Main Results:

Pulmonary fibrosis and pulmonary hypertension are identified as primary drivers of respiratory failure and mortality in pulmonary sarcoidosis.
HRCT and echocardiography are crucial for screening these advanced conditions.
While therapies for chronic inflammation and pulmonary hypertension have been explored, evidence for anti-fibrotic agents in sarcoidosis-associated pulmonary fibrosis remains limited due to underpowered studies.

Conclusions:

Advanced pulmonary sarcoidosis necessitates vigilant monitoring for fibrosis and hypertension.
Further well-powered clinical trials are required to establish effective treatments for sarcoidosis-associated pulmonary fibrosis.
A comprehensive approach addressing inflammation, hypertension, and fibrosis is crucial for managing chronic pulmonary sarcoidosis.